Abstract:Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder. As previous therapeutic trials in ALS have been severely hampered by patients’ heterogeneity, the identification of biomarkers that reliably reflect disease progression represents a priority in ALS research. Here, we used the D50 disease progression model to investigate correlations between cerebrospinal fluid (CSF) neurofilament light chain (NfL) levels and disease aggressiveness. The D50 model quantifies individual disease trajectories for each ALS patient. The value D50 provides a unified measure of a patient’s overall disease aggressiveness (defined as time taken in months to lose 50% of functionality). The relative D50 (rD50) reflects the individual disease covered and can be calculated for any time point in the disease course. We analyzed clinical data from a well-defined cohort of 156 patients with ALS. The concentration of NfL in CSF samples was measured at two different laboratories using the same procedure. Based on patients’ individual D50 values, we defined subgroups with high (<20), intermediate (20–40), or low (>40) disease aggressiveness. NfL levels were compared between these subgroups via analysis of covariance, using an array of confounding factors: age, gender, clinical phenotype, frontotemporal dementia, rD50-derived disease phase, and analyzing laboratory. We found highly significant differences in NfL concentrations between all three D50 subgroups ( p < 0.001), representing an increase of NfL levels with increasing disease aggressiveness. The conducted analysis of covariance showed that this correlation was independent of gender, disease phenotype, and phase; however, age, analyzing laboratory, and dementia significantly influenced NfL concentration. We could show that CSF NfL is independent of patients’ disease covered at the time of sampling. The present study provides strong evidence for the potential of NfL to reflect disease aggressiveness in ALS and in addition proofed to remain at stable levels throughout the disease course. Implementation of CSF NfL as a potential read-out for future therapeutic trials in ALS is currently constrained by its demonstrated susceptibility to (pre-)analytical variations. Here we show that the D50 model enables the discovery of correlations between clinical characteristics and CSF analytes and can be recommended for future studies evaluating potential biomarkers.

Neurofilaments as biomarkers in neurological disorders

Neurofilament light chain as a biomarker in neurological disorders

Neurofilaments in neurologic disease

CSF neurofilament light chain profiling and quantitation in neurological diseases

The multifaceted role of neurofilament light chain protein in non-primary neurological diseases

Emerging Trends: Neurofilament Biomarkers in Precision Neurology

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?

Blood neurofilament light: a critical review of its application to neurologic disease

Comparative analysis of neurofilaments and biomarkers of muscular damage in amyotrophic lateral sclerosis

Neurofilament heavy phosphorylated epitopes as biomarkers in ageing and neurodegenerative disease

Neurofilaments Light Chain in Neurodegenerative Dementias: A Review of Imaging Correlates

The potential of serum neurofilament as biomarker for multiple sclerosis

Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model

Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls

Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases

Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer's disease

Neurofilament light chain reference values in serum and cerebrospinal fluid: a bi-compartmental analysis in neurological diseases

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa